Sublimaze

ACCESS ALL DATA, CHEMISTRY

ACTIVE PHARMA INGREDIENTS

31 API Suppliers, 12 USDMF, 11 CEP/COS, 3 JDMF, 1 EU WC, 4 KDMF, 13 NDC API, 10 Listed Suppliers, $ API Reference Price

DEVELOPMENTS

18 Drugs in Development

18 Drugs in Development

INTERMEDIATES

5 Intermediate Suppliers

5 Intermediate Suppliers

FINISHED DOSAGE FORMULATIONS

496 FDF Dossiers, 71 FDA Orange Book, 392 Europe, 5 Canada, 2 South Africa, 26 Listed Dossiers

DRUG PRODUCT COMPOSITIONS

FILM, EXTENDED RELEASE;TRANSDERMAL - 100MCG/HR **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**, FILM, EXTENDED RELEASE;TRANSDERMAL - 12.5MCG/HR **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**, FILM, EXTENDED RELEASE;TRANSDERMAL - 25MCG/HR **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**, FILM, EXTENDED RELEASE;TRANSDERMAL - 37.5MCG/HR **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**, FILM, EXTENDED RELEASE;TRANSDERMAL - 50MCG/HR **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**, FILM, EXTENDED RELEASE;TRANSDERMAL - 75MCG/HR **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**

RELATED EXCIPIENT COMPANIES

1 SPI Pharma, 4 DKSH, 2 Boai NKY Pharmaceuticals Ltd, 1 Nanjing Well Pharmaceutical, 1 Actylis, 1 Alcedo Pharmachem, 5 BASF, 1 Huzhou Sunflower Pharmaceutical, 1 Microlex e.U, 1 Novo Excipients

EXCIPIENTS BY APPLICATIONS

8 Topical, 6 Fillers, Diluents & Binders, 5 Direct Compression, 4 Thickeners and Stabilizers, 4 Rheology Modifiers, 3 Film Formers & Plasticizers, 2 Solubilizers, 2 Granulation, 1 Controlled & Modified Release, 1 Taste Masking, 1 Coating Systems & Additives

DIGITAL CONTENT

198 News #PharmaBuzz

198 News #PharmaBuzz

GLOBAL SALES INFORMATION

3 US Medicaid Prescriptions, 370 Regulatory FDF Prices, 21 Annual Reports

MARKET PLACE

5 APIs, 21 FDF Dossiers

PATENTS & EXCLUSIVITIES

68 US Patents, 5 Health Canada Patents

REF. STANDARDS & IMPURITIES

2 EDQM, 11 Others

$ Xls

Filters

Digital Content

Create Content with PharmaCompass, ask us

NEWS #PharmaBuzz

US-China fentanyl talks hang by thread amid trade war

23 Apr 2025

// REUTERS

NLS Pharmaceutics: Mazindol Reduces Fentanyl Reward in Animals

15 Apr 2025

// PR NEWSWIRE

Enforcement Report - Week of February 26, 2025

26 Feb 2025

// FDA

United Against Fentanyl Names Ex-MADD Head To Tackle Crisis

19 Feb 2025

// BUSINESSWIRE

Aveva Launches Generic Fentanyl TDS, Third Complex TDS In 15M

17 Feb 2025

// PR NEWSWIRE

Nutriband & Kindeva to Co-Develop Fentanyl Abuse-Deterrent Patch

12 Feb 2025

// CONTRACTPHARMA

Sublimaze

Sublimaze

ACCESS ALL DATA

Browse all information

CHEMISTRY

Discover Molecule Insights

ACTIVE PHARMA INGREDIENTS

31 API Suppliers

12 USDMF

11 CEP/COS

3 JDMF

1 EU WC

4 KDMF

13 NDC API

10 Listed Suppliers

$ API Reference Price

DEVELOPMENTS

18 Drugs in Development

INTERMEDIATES

5 Intermediate Suppliers

FINISHED DOSAGE FORMULATIONS

496 FDF Dossiers

71 FDA Orange Book

392 Europe

5 Canada

2 South Africa

26 Listed Dossiers

DRUG PRODUCT COMPOSITIONS

FILM, EXTENDED RELEASE;TRANSDERMAL - 100MCG/HR **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**

FILM, EXTENDED RELEASE;TRANSDERMAL - 12.5MCG/HR **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**

FILM, EXTENDED RELEASE;TRANSDERMAL - 25MCG/HR **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**

FILM, EXTENDED RELEASE;TRANSDERMAL - 37.5MCG/HR **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**

FILM, EXTENDED RELEASE;TRANSDERMAL - 50MCG/HR **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**

FILM, EXTENDED RELEASE;TRANSDERMAL - 75MCG/HR **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**

RELATED EXCIPIENT COMPANIES

1 SPI Pharma

4 DKSH

2 Boai NKY Pharmaceuticals Ltd

1 Nanjing Well Pharmaceutical

1 Actylis

1 Alcedo Pharmachem

5 BASF

1 Huzhou Sunflower Pharmaceutical

1 Microlex e.U

1 Novo Excipients

EXCIPIENTS BY APPLICATIONS

8 Topical

6 Fillers, Diluents & Binders

5 Direct Compression

4 Thickeners and Stabilizers

4 Rheology Modifiers

3 Film Formers & Plasticizers

2 Solubilizers

2 Granulation

1 Controlled & Modified Release

1 Taste Masking

1 Coating Systems & Additives

DIGITAL CONTENT

198 News #PharmaBuzz

GLOBAL SALES INFORMATION

3 US Medicaid Prescriptions

370 Regulatory FDF Prices

21 Annual Reports

MARKET PLACE

5 APIs

21 FDF Dossiers

PATENTS & EXCLUSIVITIES

68 US Patents

5 Health Canada Patents

REF. STANDARDS & IMPURITIES

2 EDQM

11 Others

Filters

FILM, EXTENDED RELEASE;TRANSDERMAL - 100MCG/HR Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

FILM, EXTENDED RELEASE;TRANSDERMAL - 12.5MCG/HR Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

FILM, EXTENDED RELEASE;TRANSDERMAL - 25MCG/HR Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

FILM, EXTENDED RELEASE;TRANSDERMAL - 37.5MCG/HR Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

FILM, EXTENDED RELEASE;TRANSDERMAL - 50MCG/HR Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

FILM, EXTENDED RELEASE;TRANSDERMAL - 75MCG/HR Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons